Vedolizumab is a monoclonal antibody that specifically targets the α4β7 integrin, a protein expressed on the surface of certain white blood cells. It is primarily approved for the treatment of inflammatory bowel diseases (IBD) such as Crohn's Disease and Ulcerative Colitis. By inhibiting the interaction of α4β7 integrin with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), vedolizumab effectively reduces the migration of T-lymphocytes into the gastrointestinal tract, thereby alleviating inflammation.
